Compare OGN & DAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGN | DAN |
|---|---|---|
| Founded | 1923 | 1904 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.8B |
| IPO Year | 2020 | 2003 |
| Metric | OGN | DAN |
|---|---|---|
| Price | $13.76 | $26.66 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $11.25 | ★ $38.67 |
| AVG Volume (30 Days) | ★ 2.0M | 1.2M |
| Earning Date | 11-09-2026 | 10-28-2026 |
| Dividend Yield | 0.58% | ★ 1.70% |
| EPS Growth | N/A | ★ 264.10 |
| EPS | 0.95 | ★ 9.93 |
| Revenue | $6,216,000,000.00 | ★ $7,500,000,000.00 |
| Revenue This Year | N/A | $3.78 |
| Revenue Next Year | $2.51 | $48.29 |
| P/E Ratio | $14.48 | ★ $2.85 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.69 | $18.96 |
| 52 Week High | $13.83 | $39.56 |
| Indicator | OGN | DAN |
|---|---|---|
| Relative Strength Index (RSI) | 54.03 | 36.44 |
| Support Level | $13.46 | $26.07 |
| Resistance Level | $13.77 | $28.05 |
| Average True Range (ATR) | 0.04 | 0.94 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 34.78 | 13.04 |
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Dana Inc is provider of products to virtually every vehicle manufacturer in the world. Its technologies include drive systems (axles, driveshafts and transmissions); electrodynamic technologies (motors, inverters, software and control systems, battery-management systems, and fuel cell plates); sealing solutions (gaskets, seals, cam covers, and oil pan modules); thermal-management technologies (transmission and engine oil cooling, battery and electronics cooling, charge air cooling, and thermal-acoustical protective shielding); and digital solutions (active and passive system controls and descriptive and predictive analytics). The company has two operating segments: Light Vehicle and Commercial Vehicle. The Light Vehicles segment generates the majority of revenue.